

Daftar Pustaka

- Aggarwal, P. and Limaiem, F. 2022. *Reed Sternberg Cells*. [Updated 2022 Jul 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK542333/>
- Aghdam, M., & Eftekhari, K. (2017). Arch Pediatr Infect Dis. 5(3), 38345. <https://doi.org/10.5812/pedinfec.38345>
- Althuwaiqeb, S. A. *et al.* 2022. Histology, B Cell Lymphocyte. [Updated 2022 May 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK560905/>
- American Cancer Society. 2022. *Key Statistics for Hodgkin Lymphoma*. Diakses pada 24 Agustus 2022. Dapat diakses di : <https://www.cancer.org/cancer/hodgkin-lymphoma/about/key-statistics.html>
- Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., *et al.* *The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging*. CA Cancer J Clin. 2017 Mar;67(2):93-99. doi: 10.3322/caac.21388. Epub 2017 Jan 17. PMID: 28094848.
- Anagnostopoulos, I. *et al.* (2000). *Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription*. Blood, 95(4), 1443–1450.; Nam-Cha *et al.*, 2009; Swerdlow, *et al.*, 2016).
- Ansell, S. M. 2015. *Hodgkin Lymphoma: Diagnosis and Treatment*. Mayo Clin Proc. 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005. PMID: 26541251.
- Arya, L. S. *et al.* 2006. *Hodgkin's disease in Indian children: Outcome with chemotherapy alone*. Pediatr Blood Cancer. 2006; 46: 26–34. doi: 10.1002/pbc.20157
- Avagyan, A. *et al.* 2016. *Treating Adults with Hodgkin Lymphoma in the Developing World: a Hospital-Based Cohort Study from Armenia*. Asian Pac J Cancer Prev. 2016; 17: 101–104.
- Bray, F. *et al.* 2018. *Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313. PMID: 30207593.
- Cai, X. *et al.* *Accuracy of Signs, Symptoms, and Hematologic Parameters for the Diagnosis of Infectious Mononucleosis: A Systematic Review and Meta-Analysis*. J Am Board Fam Med. 2021 Nov-Dec. 34 (6):1141-1156.
- Canellos, G. P., Lister, T. A., & Young, B. D. 2006. *The lymphomas*. Philadelphia: Saunders Elsevier.
- Carbone, A. *et al.* 2016. *The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis*. International Journal of Cancer, 140(6), 1233–1245. doi:10.1002/ijc.30473

- Carbone, A. *et al.* 2017. *Epstein-Barr virus associated lymphomas in people with HIV*. Curr Opin HIV AIDS 12:39–46. Diakses pada 24 Januari 2023. Dapat diakses pada : <https://pubmed.ncbi.nlm.nih.gov/27755151/>
- Cerci, J. J. *et al.* 2010. *18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma*. J Nucl Med. 2010; 51: 1337–1343. doi: [10.2967/jnumed.109.073197](https://doi.org/10.2967/jnumed.109.073197)
- Chatterjee, K. *et al.* 2019. *The interplay between Epstein-Bar virus (EBV) with the p53 and its homologs during EBV associated malignancies*. Heliyon. 2019 Nov 14;5(11):e02624. doi: 10.1016/j.heliyon.2019.e02624. PMID: 31840114; PMCID: PMC6893087.
- Cickusić, E. *et al.* 2007. *Association of Hodgkin's lymphoma with Epstein Barr virus infection*. Bosn J Basic Med Sci. 2007 Feb;7(1):58-65. doi: 10.17305/bjbm.2007.3092. PMID: 17489771; PMCID: PMC5802289.
- Clarke, C. A. *et al.* 2001. *Epstein-Barr virus and survival after Hodgkin disease in a population-based series of women*. Cancer, 91(8), 1579–1587. doi:10.1002/1097-0142(20010415)91:8<1579::aid-cnrc1169>3.0.co;2-l
- Connors, J. M. 2005. *State-of-the-art therapeutics: Hodgkin lymphoma*. J Clin Oncol. 2005;23(26):6400-6408.
- Diefenbach, C. S. *et al.* 2015. *Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era*. British Journal of Haematology, 171(4), 530–538. doi:10.1111/bjh.13634
- Diehl V. *et al.* 2010. *Clinical features and prognosis of nodular sclerosis Hodgkin lymphoma in relation to other Hodgkin lymphoma subtypes: results from the European HN35 trial*. Int J Radiat Oncol Biol Phys. 2010;76(1):4-10.
- Dematapitiya, C. *et al.* 2019. *Cold type autoimmune hemolytic anemia- a rare manifestation of infectious mononucleosis; serum ferritin as an important biomarker*. BMC Infect Dis. 2019 Jan 18;19(1):68. doi: 10.1186/s12879-019-3722-z. PMID: 30658594; PMCID: PMC6339345.
- Farrell, K., & Jarrett, R. F. (2011). *The molecular pathogenesis of Hodgkin lymphoma*. Histopathology, 58(1), 15–25. doi:10.1111/j.1365-2559.2010.03705.x
- Farid, Y. *et al.* 2022. *Biochemistry, Hemoglobin Synthesis*. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK536912/>
- Flowers, C.R., *et al.* 2011. *Clinical, Molecular, and Environmental Risk Factors for Hodgkin Lymphoma*. Advances in Hematology, 2011. <https://doi.org/10.1155/2011/736261>
- Glavina-Durdov, M. *et al.* 2001. *Assessment of the prognostic impact of the Epstein–Barr virus-encoded latent membrane protein-1 expression in Hodgkin’s disease*. British Journal of Cancer, 84(9), 1227–1234. doi:10.1054/bjoc.2001.1774
- Glaser, S. L. 1987. *Regional variation in Hodgkin’s disease incidence by histologic subtype in the U.S. Cancer 1987*;60:2841–7.
- Greer, J. P. *et al.* 1986. *Lymphocyte-depleted hodgkin’s disease. Clinicopathologic review of 25 patients*. The American Journal of Medicine, 81(2), 208–214. doi:10.1016/0002-9343(86)90253-6

- Grover, N. S. and Park, S. I. 2015. Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy. MDPI. Pharmaceuticals 2015, 8(3), 607-636; <https://doi.org/10.3390/ph8030607>
- Gambhir, S. 2015. *Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies*. World J Gastroenterol. 2015 Mar 21;21(11):3174-83. doi: 10.3748/wjg.v21.i11.3174. PMID: 25805923; PMCID: PMC4363746.
- Gobbi, P. G., Ferreri, A. J., Ponzoni, M., Levis, A. 2013 Hodgkin lymphoma. Crit Rev Oncol Hematol. 2013 Feb;85(2):216-37. doi: 10.1016/j.critrevonc.2012.07.002. Epub 2012 Aug 4. PMID: 22867814.
- Grotto, I. et al. 2003. *Clinical and laboratory presentation of EBV positive infectious mononucleosis in young adults*. Epidemiol Infect. 2003 Aug;131(1):683-9. doi: 10.1017/s0950268803008550. PMID: 12948368; PMCID: PMC2870009.
- Gulley, M. L. et al. 2002. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol. 2002 Feb;117(2):259-67. doi: 10.1309/MMAU-0QYH-7BHA-W8C2. PMID: 11863222.
- Hartmann, S. and Eichenauer, D.A. 2020. *Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma*. Pathology. 2020 Jan;52(1):142-153. doi: 10.1016/j.pathol.2019.10.003. Epub 2019 Nov 28. PMID: 31785822.
- Hasenclever, D. and Diehl, V. *A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease*. N Engl J Med. 1998 Nov 19;339(21):1506-14. doi: 10.1056/NEJM199811193392104. PMID: 9819449.
- Henry H. et al. 2013. Age-Specific Prevalence of Epstein–Barr Virus Infection Among Individuals Aged 6–19 Years in the United States and Factors Affecting Its Acquisition, The Journal of Infectious Diseases, Volume 208, Issue 8, 15 October 2013, Pages 1286–1293, <https://doi.org/10.1093/infdis/jit321>
- Hjalgrim, H. et al. The epidemiology of EBV and its association with malignant disease. In: Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge University Press, Cambridge; 2007. PMID: 21348109.
- Hoover K. and Higginbotham, K. 2022. *Epstein Barr Virus*. [Updated 2022 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559285/>
- Horesh, N., and Horowitz, N. A. 2014. *Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy*. Rambam Maimonides Med J. 2014 Oct 29;5(4):e0038. doi: 10.5041/RMMJ.10172. PMID: 25386354; PMCID: PMC4222427.
- Howell, D. A., et al. (2019). *Disease-related factors affecting timely lymphoma diagnosis: a qualitative study exploring patient experiences*. British Journal of General Practice, 69(679), e134–e145. doi:10.3399/bjgp19x701009
- Hsi, E. D. 2019. *Hematopathology*. Philadelphia, PA: Elsevier.

- Hu, J. *et al.* 2019. *Epstein-Barr virus infection is associated with a higher Child-Pugh score and may predict poor prognoses for patients with liver cirrhosis*. BMC Gastroenterol. 2019 Jun 18;19(1):94. doi: 10.1186/s12876-019-
- Huang, S.C. 2012. *Hypoalbuminaemia is an independent predictor for hemophagocytic lymphohistiocytosis in childhood Epstein-Barr virus-associated infectious mononucleosis*. Eur J Haematol. 2012 Nov;89(5):417-22. doi: 10.1111/ejh.12006. Epub 2012 Sep 7. PMID: 22897479.
- Jaffe, E. S. *et al.* 2016. *Hematopathology*. Philadelphia, PA: Elsevier Ltd
- Jamil, A., and Mukkamalla, S. K. R. 2022. *Lymphoma*. [Updated 2022 Jul 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK560826/>
- Kadin, M. E. *et al.* 1988. *Expression of T-cell antigens on Reed-Sternberg cells in a subset of patients with nodular sclerosing and mixed cellularity Hodgkin's disease*. Am J Pathol. 1988 Feb;130(2):345-53. PMID: 2963547; PMCID: PMC1880530.
- Kanakry, J. A. *et al.* *The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases*. Blood. 2016;127(16):2007-2017.
- Kaseb, H., Babiker, H. M. 2022. *Hodgkin Lymphoma*. [Updated 2022 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK499969/>
- Keegan, T. *et al.* 2005. *Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study*. J Clin Oncol. 2005 Oct 20;23(30):7604-13. doi: 10.1200/JCO.2005.02.6310. Epub 2005 Sep 26. PMID: 16186595.
- KEMENKES. 2015. Data dan Kondisi Limfoma di Indonesia. Diakses pada 24 Agustus 2021. Dapat diakses pada : https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwiOvImHw-D8AhVQTWwGHbc0A6oQFnoECCIQAQ&url=https%3A%2F%2Fd3v.kemkes.go.id%2Fpublikasi%2Fpage%2Fprotocol%2Fdata-dan-kondisi-limfoma-di-indonesia&usq=AOvVaw380QAO_7HSSCfqDU7kUG3o
- Koh, Y. W. *et al.* 2012. *The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages*. Oncologist. 2012;17(6):871-80. doi: 10.1634/theoncologist.2012-0034. Epub 2012 May 15. PMID: 22588324; PMCID: PMC3380887.
- Kumar, V. *et al.* 2018. *Robbins basic pathology*. 10th ed. Philadelphia: Elsevier/Saunders. 474 – 478.
- Lertbutsayanukul, C., Tharavej, C., Klaikeaw, N., Prayongrat, A., Lowanitchai, C., & Sriuranpong, V. (2017). High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. Thoracic Cancer, 8(3), 219–228. <https://doi.org/10.1111/1759-7714.12427>

- Li, W. *et al.* 2009. *Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma*. *Int J Clin Exp Pathol*. 2009 Jan 1;3(3):238-43. PMID: 20224721; PMCID: PMC2836501.
- Li, YX. *et al.* 2010. *Hodgkin lymphoma in China: a review of 2328 cases presenting with predominantly nodal disease*. *Ann Oncol*. 2010;21(3):683-689.
- Lin, Z. *et al.* 2017. *Prognostic value of peripheral blood absolute lymphocyte/monocyte count ratio at diagnosis in patients with classical Hodgkin lymphoma*. *Oncotarget*. 2017;8(15):24563-24572.
- Lister, T.A. *et al.* 1989. *Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting*. *J Clin Oncol*. 1989;7(11):1630-1636.
- Liu, T.-Y., Wu, S.-J., Huang, M.-H., Lo, F.-Y., Tsai, M.-H., Tsai, C.-H., Hsu, S.-M., & Lin, C.-W. (2010). EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis. *Molecular Cancer*, 9(1), 32. <https://doi.org/10.1186/1476-4598-9-32>
- Luca, D. 2022. *Hodgkin lymphoma Nodular sclerosis*. Diakses pada 24 Januari 2023. Dapat diakses di : <https://www.pathologyoutlines.com/topic/lymphomanonbnshl.html>
- Luca, D. 2022. *Hodgkin lymphoma CHL lymphocyte rich*. Diakses pada 24 Januari 2023. Dapat diakses di : www.pathologyoutlines.com/topic/lymphomanonBLRHL.html
- Mallick, I. 2022. *An Overview of Nodular Sclerosing Hodgkin Lymphoma*. Diakses pada 23 Juni 2022. Dapat diakses pada : [https://www.verywellhealth.com/nodular-sclerosing-hodgkins-lymphoma-2252198#:~:text=Nodular%20sclerosing%20Hodgkin%20lymphoma%20\(NSHL,by%20a%20lymph%20node%20biopsy](https://www.verywellhealth.com/nodular-sclerosing-hodgkins-lymphoma-2252198#:~:text=Nodular%20sclerosing%20Hodgkin%20lymphoma%20(NSHL,by%20a%20lymph%20node%20biopsy).
- Massini, G. *et al.* 2009. *EBV in Hodgkin Lymphoma*. *Mediterr J Hematol Infect. Dis*. 2009 Nov 24;1(2):e2009013. doi: 10.4084/MJHID.2009.013. PMID: 21416003; PMCID: PMC3033177.
- McDermott, M. R., & Smrkovski, L. L. 2013. Infectious mononucleosis. *Journal of Infectious Diseases*, 208(8), 1286-1287. doi: 10.1093/infdis/jit358.
- Medeiros, L. J., and Greiner, T. C. 1995. *Hodgkin's disease*. *Cancer*. 1995 Jan 1;75(1 Suppl):357-69. doi: 10.1002/1097-0142(19950101)75:1+<357::aid-cnrcr2820751318>3.0.co;2-a. PMID: 8001007.
- Moccia, A. A. *et al.* 2012. *International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era*. *J Clin Oncol*. 2012 Sep 20;30(27):3383-8. doi: 10.1200/JCO.2011.41.0910. Epub 2012 Aug 6. PMID: 22869887.
- Mottok, A. and Steidl, C. 2018, *Biology of classical Hodgkin lymphoma: Implications for prognosis and novel therapies*, *Blood*, 131, 1654–1665.
- Moman, R. N. *et al.* 2022. *Physiology, Albumin*. [Updated 2022 Jan 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459198/>
- Mozaheb, Z. (2013). *Epidemiology of hodgkin's lymphoma*. *Health*, 05(05), 17–22. doi:10.4236/health.2013.55a003.

- Myriam, B. D. *et al.* 2016. *Prognostic significance of Epstein-Barr virus (EBV) infection in Hodgkin lymphoma patients.* J Infect Chemother. 2017 Mar;23(3):121-130. doi: 10.1016/j.jiac.2016.09.004. Epub 2016 Dec 26. PMID: 28034523.
- National Cancer Institute. 2022. *The Revised European American Lymphoma Classification (REAL). SEER training module.* Diakses pada 24 Agustus 2022. Dapat diakses di : <https://training.seer.cancer.gov/lymphoma/abstract-code-stage/morphology/real.html>
- National Cancer Institute. 2022. Reed-Sternberg cell. [Internet]; <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/reed-sternberg-cell>.
- National Health Service UK. 2021. *Hodgkin lymphoma.* Diakses pada : 24 Agustus 2022. Akses: www.nhs.uk/conditions/Hodgkinlymphoma/#:~:text=Hodgkin%20lymphoma%20is%20a%20relatively,tremendous%20strain%20on%20the%20body.
- Obtel, M., *et al.* 2017. *Factors Associated with Delayed Diagnosis of Lymphomas: Experience with Patients from Hematology Centers in Morocco.* Asian Pac J Cancer Prev. 2017 Jun 25;18(6):1603-1610. doi: 10.22034/APJCP.2017.18.6.1603. PMID: 28669176; PMCID: PMC6373802.
- Owzarczyk, A. B. and Smith, L. 2022. *CHL lymphocyte depleted.* Diakses pada 24 Januari 2023. Dapat diakses di : <https://www.pathologyoutlines.com/topic/lymphomanonBlymphocytedepleted.html>
- Peng, H. *et al.* 2016. *Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy.* Scientific Reports, 6(1), 22000. <https://doi.org/10.1038/srep22000>
- Piccaluga, P. P. *et al.* 2010. *Pathobiology of hodgkin lymphoma.* Adv Hematol. 2011;2011:920898. doi: 10.1155/2011/920898. Epub 2010 Dec 22. PMID: 21253495; PMCID: PMC3021869.
- Piña-Oviedo, S. 2016. *Primary Mediastinal Classical Hodgkin Lymphoma.* Adv Anat Pathol. 2016 Sep;23(5):285-309. doi: 10.1097/PAP.0000000000000119. PMID: 27441757.
- Porrata, L. F., *et al.* 2012. *Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma.* British Journal of Haematology, 157(3), 321–330. doi:10.1111/j.1365-2141.2012.09067.x
- Prayongrat, A. *et al.* (2017). *Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma.* Journal of Radiation Research, 58(4), 509–516. <https://doi.org/10.1093/jrr/rrw128>
- Qi, Z. L. *et al.* 2012. *Comparison of three methods for the detection of Epstein-Barr virus in Hodgkin's lymphoma in paraffin-embedded tissues.* Molecular Medicine Reports, 7(1), 89–92. doi:10.3892/mmr.2012.1163
- Rejthar, A. *et al.* 1976. *Hodgkin's lymphoma -- prognosis as related to histology, clinical stage and treatment.* Neoplasma. 1976;23(5):559-66. PMID: 980183.
- Rosai, J. 2004. *Lymph Nodes. Rosai and Ackerman Surgical Pathology.* 9th Ed. Mosby. PP.1877–2016.
- Saha, A. dan Robertson, E. S. 2011. *Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.* Clin Cancer Res. 2011 May 15;17(10):3056-63. doi:

10.1158/1078-0432.CCR-10-2578. Epub 2011 Mar 3. PMID: 21372216; PMCID: PMC4287361.

- Sehgal, R. *et al.* 2013. *Correlation of pretreatment serum albumin with outcome in patients with Hodgkin's lymphoma: results of a large cohort study.* Clin Lymphoma Myeloma Leuk. 2013;13(2):222-229.
- Sureshbabu, J. 2021. *Pediatric Mononucleosis and Epstein-Barr Virus Infection.* Medscape. Retrieved March 12, 2023, from https://emedicine.medscape.com/article/963894-overview?icd=login_success_gg_match_norm#showall
- Sethi, T. *et al.* 2016. *Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma.* Therapeutic Advances in Hematology, 8(1), 13–20. doi:10.1177/2040620716676256
- Shanbhag, S. and Ambinder, R. F. *Hodgkin lymphoma: A review and update on recent progress.* CA Cancer J Clin. 2018 Mar;68(2):116-132. doi: 10.3322/caac.21438. Epub 2017 Dec 1. PMID: 29194581; PMCID: PMC5842098.
- Shamoon, R.P. *et al.* 2018. *Overview and outcome of Hodgkin's Lymphoma: Experience of a single developing country's oncology centre.* PLoS One. 2018 Apr 12;13(4):e0195629. doi: 10.1371/journal.pone.0195629. PMID: 29649329; PMCID: PMC5896958.
- Shannon-Lowe, C. *et al.* 2017. *Epstein-Barr virus-associated lymphomas.* Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):20160271. doi: 10.1098/rstb.2016.0271. PMID: 28893938; PMCID: PMC5597738.
- Solal-Celigny, P. *et al.* 2004. *Follicular lymphoma international prognostic index.* Blood. 2004;104(5):1258-1265.
- Son, K. H. and Shin, M. Y. 2011. *Clinical features of Epstein-Barr virus-associated infectious mononucleosis in hospitalized Korean children.* Korean J Pediatr. 2011 Oct;54(10):409-13. doi: 10.3345/kjp.2011.54.10.409. Epub 2011 Oct 31. PMID: 22232623; PMCID: PMC3250594.
- Siegel, R. L., *et al.* 2022. *Cancer statistics, 2022.* CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12. PMID: 35020204.
- Singh, R. *et al.* 2015. *Lymphocyte Depleted Hodgkin's Lymphoma Presented with Haemolytic Anemia: A Case Report and Literature Review.* J Maxillofac Oral Surg. 2015 Mar;14(Suppl 1):317-22. doi: 10.1007/s12663-013-0528-1. Epub 2013 May 5. PMID: 25861191; PMCID: PMC4379286.
- Sugimoto, T. and Watanabe, T. 2016. *Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis.* J Clin Exp Hematop. 2016;56(1):1-19. doi: 10.3960/jslrt.56.1. PMID: 27334853; PMCID: PMC6247780.
- Sung, H. *et al.* *Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.* CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
- Swerdlow, S. H. *et al.* The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390

- Swerdlow, S.H. *et al.* 2017. *WHO classification of tumours of haematopoietic and lymphoid tissues*. Lyon: International Agency for Research on Cancer. ISBN : 928324494X
- SIMETRIS. Data rekam medis SIMETRIS RSUP Dr. Sardjito Yogyakarta. Diakses pada 10 Juli 2022.
- Taylor, G. S. *et al.* 2015. The immunology of Epstein-Barr virus-induced disease. *Annu Rev Immunol.* 2015;33:787-821. doi: 10.1146/annurev-immunol-032414-112326. Epub 2015 Feb 11. PMID: 25706097.
- Tigner, A. *et al.* 2022. *Histology, White Blood Cell*. [Updated 2022 Nov 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK563148/>
- The Global Cancer Observatory. 2020. *Hodgkin lymphoma 2020*. Diakses pada 13 Desember 2022 dapat diakses pada : <https://gco.iarc.fr/today/data/factsheets/cancers/33-Hodgkin-lymphoma-fact-sheet.pdf>
- The Global Cancer Observatory. 2021. *Indonesia 2020*. Diakses pada 13 Desember 2022 dapat diakses pada : <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf>
- Thida, A. M. and Tun, A. M. 2022. *Lymphocyte Depleted Hodgkin Lymphoma*. [Updated 2022 Jun 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK556042/>
- Thyss, A. *et al.* 2014. *Hodgkin's Lymphoma in Older Patients: an Orphan Disease?*. *Mediterr J Hematol Infect Dis.* 2014 Jul 1;6(1):e2014050. doi: 10.4084/MJHID.2014.050. PMID: 25045458; PMCID: PMC4103506.
- Vassilakopoulos, T. *et al.* 2001. *Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites*. *Eur J Haematol.* 2001 Nov-Dec;67(5-6):279-88. doi: 10.1034/j.1600-0609.2001.00561.x. PMID: 11872075.
- Visco, C. *et al.* 2019. *Prognostic role of blood cell counts in patients with Hodgkin lymphoma*. *Mediterr J Hematol Infect Dis.* 2019;11(1):e2019048.
- Vockerodt, M. and Yap, L. F., Shannon-Lowe, C., Curley, H., Wei, W., Vrzalikova, K., Murray, P. G. 2015. *The Epstein-Barr virus and the pathogenesis of lymphoma*. *J Pathol.* 2015 Jan;235(2):312-22. doi: 10.1002/path.4459. PMID: 25294567
- Wang, Q. *et al.* *Tumor Suppressor p53 Stimulates the Expression of Epstein-Barr Virus Latent Membrane Protein 1*. *J Virol.* 2017 Sep 27;91(20):e00312-17. doi: 10.1128/JVI.00312-17. PMID: 28794023; PMCID: PMC5625482.
- Weniger, M. A. and Küppers, R. 2016. *NF- κ B deregulation in Hodgkin lymphoma*. *Semin Cancer Biol.* 2016 Aug;39:32-9. doi: 10.1016/j.semcancer.2016.05.001. Epub 2016 May 21. PMID: 27221964.
- Winter, J.R. *et al.* 2019. *Predictors of Epstein-Barr virus serostatus in young people in England*. *BMC Infect Dis.* 2019 Nov 28;19(1):1007. doi: 10.1186/s12879-019-4578-y. PMID: 31779585; PMCID: PMC6883578.



UNIVERSITAS
GADJAH MADA

**STATUS INFEKSI VIRUS EPSTEIN BARR PADA LIMFOMA HODGKIN SERTA KAITANNYA DENGAN
PARAMETER KLINIS DAN**

HEMATOLOGIS PASIEN DI RSUP DR. SARDJITO

VAUSTINO ABADI SOEHERMAN, Dr. dr. Indrawati, Sp.PA (K); Dewi Kartikawati Paramita, S.Si, M.Si, Ph.D; Dr. dr. K.

Universitas Gadjah Mada, 2023 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Wright, M. F. and Mason, E. 2022. *Hodgkin lymphoma Classic Hodgkin lymphoma*. Diakses pada 24 Januari 2023. Dapat diakses di :
<https://www.pathologyoutlines.com/topic/lymphomanonBclassic.html>

Xia, L. *et al.* 2018. *Role of the NF κ B-signaling pathway in cancer*. *Onco Targets Ther.* 2018 Apr 11;11:2063-2073. doi: 10.2147/OTT.S161109. PMID: 29695914; PMCID: PMC5905465.

Yakimchuk, K. *et al.* 2011. *Effect of ligand-activated estrogen receptor beta on lymphoma growth in vitro and in vivo*. *Leukemia*. 2011;25:1103–10. doi: 10.1038/leu.2011.68.

Young, N. A. and Al-Saleem, T. 2008. *CHAPTER 24 - Lymph Nodes: Cytomorphology and Flow Cytometry. Comprehensive Cytopathology* 3rd Ed, W.B. Saunders, 2008, Pages 671-711, ISBN 9781416042082, <https://doi.org/10.1016/B978-141604208-2.10024-7>. (<https://www.sciencedirect.com/science/article/pii/B9781416042082100247>)

Zhang, T. *et al.* 2018. *Epstein Barr Virus Infection Affects Function of Cytotoxic T Lymphocytes in Patients with Severe Aplastic Anemia*. *Biomed Res Int.* 2018 May 14;2018:6413815. doi: 10.1155/2018/6413815. PMID: 29862282; PMCID: PMC5976969.